Objective To investigate the association between treatment with an angiotensin receptor
blocker and clinical outcomes in patients with ST segment elevation myocardial infarction …

Background Patients with acute myocardial infarction (AMI) are usually treated with
angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin receptor blockers (ARBs) …

Introduction: Ventricular remodeling starts very early after the onset of an acute myocardial
infarction (AMI), and can be prevented by ACE-inhibitors. However, very limited data are …

This is an evidence report prepared by the University of Connecticut/Hartford Hospital
Evidence-based Practice Center (EPC) concerning the benefits and harms associated with …

There is a paucity of evidence on the impact of angiotensin-converting enzyme inhibitors
(ACEi) and angiotensin receptor blockers (ARB) on long-term outcomes in patients with …

Editor—Verma and Strauss say that, compared with angiotensin converting enzyme (ACE)
inhibitors, angiotensin receptor blockers do not reduce (and may increase) the risk of …

Aim of study: Angiotensin‐converting enzyme (ACE) inhibitors prolong life, lower the
progression of heart failure, and decrease the need for hospitalizations in patients after …

Background ACE inhibitors attenuate the detrimental effects of angiotensin II, and improve
survival and reduce morbidity in patients with acute myocardial infarction and evidence of …

It is now clear that angiotensin-converting enzyme (ACE) inhibitors have an important role in
the management of patients after myocardial infarction. Several clinical trials have shown …

Objective To evaluate the effect of angiotensin receptor blockers on the risk of myocardial
infarction in patients at risk for cardiovascular events. Design Systematic review of controlled …